Role of genomic science in males with breast cancer
Mary L Schmitt1, Suzanne M Mahon, Kelly Mcallister
1Mary L. Schmitt is a Clinical Genetics Nurse Practitioner at Tufts Medicine/Lowell General Hospital in Lowell, MA. Suzanne M. Mahon is Professor Emeritus with the Department of Internal Medicine, School of Medicine at Trudy Busch Valentine School of Nursing in Saint Louis University, St. Louis, MO. Kelly McAllister is a Breast Health Nurse Practitioner with the Breast Cancer Risk Assessment Program at Tufts Medicine/Lowell General Hospital.
Abstract:
Studies have shown that individuals assigned male at birth with a first-degree relative diagnosed with breast cancer have approximately twice the risk of developing breast cancer. Advances in genomic science have revolutionized cancer care. However, many nurses and nursing students have received little formal education in genomic science. This foundational knowledge, including proper use of terminology, is critical to providing comprehensive and safe genomic care. Nurses also play a significant role in collecting family health histories and in identifying and educating males and their families on the benefits of germline biomarker testing. This article illustrates the role of genomic science in assessing risk and treating breast cancer in males, and its implications for nursing practice. Treatment may include a combination of surgery, radiotherapy, systemic therapies, and regimens with genomic-guided targeted agents.
More Related Videos
Related Concept Videos
Genomics
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Pharmacogenomics: Identification of New Drug Targets
Epigenetic Regulation


